Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI
Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Source: targetedonc.com